Efficacy, safety, tolerability, and PK of the HDAC inhibitor resminostat in sorafenib-refractory hepatocellular carcinoma (HCC): Phase II SHELTER study.

被引：0
|
作者：
Bitzer, Michael
Horger, Marius
Ganten, Tom M.
Lauer, Ulrich M.
Woerns, Marcus A.
Siveke, Jens T.
Dollinger, Matthias M.
Gerken, Guido
Wege, Henning
Giannini, Edoardo G.
Zagonel, Vittorina
Cillo, Umberto
Trevisani, Franco
Santoro, Armando
Montesarchio, Vincenzo
Hauns, Bernhard
Asche, Julia
Jankowsky, Ruediger
Mais, Anna
Hentsch, Bernd
机构：
[1] Univ Tubingen, Med Univ Clin, Tubingen, Germany
[2] Univ Tubingen, Tubingen, Germany
[3] Heidelberg Univ, Dept Internal Med, Heidelberg, Germany
[4] Med Univ Clin, Mainz, Germany
[5] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany
[6] Univ Halle Wittenberg, Dept Internal Med, D-06108 Halle, Germany
[7] Univ Duisburg Essen, Dept Gastroenterol & Hepatol, Essen, Germany
[8] Univ Hosp Hamburg Eppendorf, Hamburg, Germany
[9] Univ Genoa, Dept Internal Med, Gastroenterol Unit, I-16126 Genoa, Italy
[10] Ist Oncol Veneto IRCCS, Padua, Italy
[11] Azienda Univ Padova, Hepatobiliary Surg & Liver Transplant Unit, Padua, Italy
[12] Univ Bologna, Bologna, Italy
[13] Humanitas Canc Ctr, Dept Oncol, Rozzano, Italy
[14] UO Oncol Osped Cotugno Napoli, Naples, Italy
[15] 4SC AG, Planegg Martinsried, Germany
[16] 4SC AG, Martinsried, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4115
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Clinical update on a phase I/II trial of HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): The SHELTER study.
    Bitzer, M.
    Horger, M.
    Ganten, T. M.
    Ebert, M. P.
    Siveke, J. T.
    Woerns, M. A.
    Dollinger, M. M.
    Gerken, G.
    Scheulen, M. E.
    Mais, A.
    Jankowsky, R.
    Hauns, B.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] CLINICAL UPDATE ON THE PHASE I/II TRIAL OF HDAC INHIBITOR RESMINOSTAT IN PATIENTS WITH SORAFENIB-RESISTANT HEPATOCELLULAR CARCINOMA (HCC) - THE SHELTER STUDY
    Bitzer, Michael
    Horger, Markus
    Ganten, Tom
    Ebert, Matthias P.
    Siveke, Jens T.
    Woerns, Marcus A.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    Mais, Anna
    Jankowsky, Ruediger
    Hauns, Bernhard
    Hentsch, Bernd
    Lauer, Ulrich M.
    ANNALS OF ONCOLOGY, 2011, 22 : v76 - v76
  • [3] Clinical update on the SHELTER study: A phase I/II trial of the HDAC inhibitor resminostat in patients with sorafenib-reistant hepatocellular carcinoma (HCC).
    Bitzer, M.
    Horger, M.
    Ganten, T.
    Ebert, M. P.
    Woerns, M. A.
    Dollinger, M. M.
    Mais, A.
    Hauns, B.
    Hentsch, B.
    Lauer, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [4] Investigation of the HDAC inhibitor resminostat in patients with sorafenib-resistant hepatocellular carcinoma (HCC): Clinical data from the phase I/II SHELTER study
    Bitzer, Michael
    Horger, Marius
    Ganten, Tom M.
    Siveke, Jens T.
    Woerns, Marcus A.
    Dollinger, Matthias M.
    Gerken, Guido
    Scheulen, Max E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [5] Phase II trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC)
    He, Aiwu Ruth
    Tesfaye, Anteneh
    Smith, Daniel
    Marshall, John
    Pishvaian, Michael J.
    Smaglo, Brandon George
    Weiner, Louis M.
    Dorsch-Vogel, Karen
    Wang, Hongkun
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] First clinical data of resminostat, a novel oral histone deacetylase (HDAC) inhibitor, in patients with hepatocellular carcinoma (HCC): The SHELTER study
    Bitzer, M.
    Horger, M.
    Ebert, M. P.
    Ganten, T.
    Woerns, M. A.
    Hauns, B.
    Mais, A.
    Jankowsky, R.
    Hentsch, B.
    Lauer, U. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
    Andrew Gabrielson
    Anteneh A. Tesfaye
    John L. Marshall
    Michael J. Pishvaian
    Brandon Smaglo
    Reena Jha
    Karen Dorsch-Vogel
    Hongkun Wang
    Aiwu Ruth He
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1073 - 1079
  • [8] Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma
    Gabrielson, Andrew
    Tesfaye, Anteneh A.
    Marshall, John L.
    Pishvaian, Michael J.
    Smaglo, Brandon
    Jha, Reena
    Dorsch-Vogel, Karen
    Wang, Hongkun
    He, Aiwu Ruth
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (05) : 1073 - 1079
  • [9] Phase 2 trial of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma (HCC)
    He, Aiwu R.
    Shivapurkar, Narayan
    Tesfaye, Anteneh A.
    Wang, HongKun
    Pishvaian, Michael J.
    Smaglo, Brandon G.
    Marshall, John
    Dorsch-Vogel, Karen
    Kachhela, Jaydeep
    HEPATOLOGY, 2014, 60 : 865A - 866A
  • [10] Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
    Yau, Thomas
    Wong, Hilda
    Chan, Pierre
    Yao, T. J.
    Pang, R.
    Cheung, T. T.
    Fan, S. T.
    Poon, Ronnie T.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2384 - 2390
12345